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2ABSTRACT
Background: Hypertension is associated with cerebrovascular remodeling and 
endothelial dysfunction, which may reduce cerebral vasomotor reactivity to CO2. 
Treatment combining blood pressure (BP) reduction with inhibition of vascular effects of 
angiotensin II may reverse these changes. However, the reduction in BP at the onset of 
treatment can compromise cerebral perfusion and exhaust vasomotor reserve, leading 
to impaired CO2 reactivity.
Methods: 11 patients with newly diagnosed, untreated mild to moderate hypertension, 
9 men, 2 women, age (mean (SD)) 52 (9) years, and 8 controls, 7 men, 1 woman, age 
46 (10) years were studied. Patients received losartan/hydrochlorothiazide (50/12.5 or 
100/25 mg) to reduce BP to < 140 / < 90 mmHg within 1-2 weeks. BP (Finapres), heart 
rate, CBFV (cerebral blood flow-velocity, transcranial Doppler), cerebrovascular 
resistance, and CO2 reactivity were measured at baseline, after the rapid BP reduction, 
and after long- term treatment (3-4 months).
Results: At baseline, hypertension was not associated with reduced CO2 reactivity. 
Treatment effectively lowered BP from 148(12)/ 89(7) to 130(15)/ 80(9) after 1-2 weeks 
and 125(10)/ 77(7) mmHg after 3-4 months (p = 0.003). CO2 reactivity was not affected 
by the reduction in BP within 2 weeks, and long term treatment did not augment 
reactivity.
Conclusions: In hypertension without diabetes or advanced cerebrovascular disease, 
CO2 reactivity is not reduced, and rapid normalization (within 2 weeks) of BP does not 
exhaust vasomotor reserve. CO2 reactivity did not change between 2 and 12 weeks of 
treatment, which argues against a direct vascular effect of angiotensin II inhibition within 
this period.
Key Words: cerebrovascular circulation; carbon dioxide; Transcranial Doppler 
ultrasonography; vascular response; hypocapnia; hypercapnia
3INTRODUCTION
Hypertension causes remodeling of cerebral arteries with increases in wall
1 0 thickness/lumen ratio ' and impaired endothelium-mediated vasodilatation.2 These
changes may reduce cerebrovascular reactivity to CO2.3 Cerebral vasomotor responses
to changes in arterial CO2 (CVMR) have been widely used as a clinical test to evaluate
A ^vascular function in patients with carotid stenosis.45 Relatively few studies have 
investigated CVMR in hypertension. Most found that CVMR was reduced in 
hypertension and could be restored with treatment.6,7,8,9 Unfortunately, blood pressure 
(BP) was not recorded during the CVMR tests in all but one 9 of these studies. BP is 
affected substantially by changes in CO2, and the influence of BP on cerebral blood flow 
will confound CVMR.10 Moreover, whether this BP response to CO2 is altered by 
hypertension is unknown. Therefore, further evaluation of CVMR in hypertension is 
warranted and should include evaluation of the interaction of CO2, BP and cerebral 
blood flow.11
Although treatment of hypertension has been shown convincingly to reduce
Q  H O
stroke risk, and may also beneficially affect onset and progression of dementia,212 
considerable uncertainty remains about the possible adverse effects of BP lowering 
treatment on cerebral perfusion.13 Structural changes and endothelial dysfunction may
reduce the capacity of cerebral vessels to compensate for the reduction BP, creating
1 ^susceptibility to brain ischemia.
Angiotensin II is implicated in the structural and functional cerebrovascular
•j
changes in hypertension.2 Treatment blocking the effects of angiotensin II may have
1 4  1 ^beneficial cerebrovascular effects (outside its effects on BP) and restore CVMR.
However, clinical trials to date have provided conflicting results and this issue remains to
0 10be resolved.212
In this study, we have tested the hypothesis that impaired vasodilatatory 
capacity in hypertensive patients causes a (further) reduction in CVMR when BP is 
lowered. Moreover, we hypothesized that patients are most susceptible for this 
impairment at the onset of treatment. We investigated CVMR in patients with untreated 
hypertension, using a modified CVMR test to account for effects of BP on CVMR and to
4address effects of hypertension on the BP response to CO2. Subsequently, we 
investigated longitudinal effects of antihypertensive treatment on CVMR by measuring 
CVMR at onset of treatment ("short term”: after rapid normalization of BP within 1 -2 
weeks) and again after 3-4 months ("long term”). We used hydrochlorothiazide 
combined with losartan to investigate the short term and long term effects of 
angiotensine II blockade on CVMR.
MATERIALS AND METHODS 
Subjects
This study was conducted in a subgroup of subjects who participated in research 
on dynamic cerebral autoregulation in hypertension.16 11 patients with mild to moderate 
hypertension (9 men, 2 women) with a mean age of 52 (SD 9) years (range, 39 -  66), 
and 8 healthy subjects (7 men, 1 woman) with a mean age of 46 (SD 10) years (range, 
38 - 66) participated (Table 1 ). Based on the variance of the CVMR measurements, 10 
this study had 90 % power to detect small changes in CVMR (1.5 %/mm Hg).
All patients had recently been diagnosed with hypertension (up to 3 months prior 
to enrolment) and had not yet started treatment, nor had they received prior 
antihypertensive treatment. Classification of hypertension (JNC 7 and ESC/ESH 2007; 
mild to moderate, stage 1-2) was based on the average of cuff BP measurements during
17at least two office visits.. Participants underwent a thorough medical history and 
physical examination, as well as blood chemistry evaluation and echocardiography, to 
exclude angina pectoris, myocardial infarction, heart failure, diabetes, renal disease, 
lung disease, or history of stroke. None were current smokers, and none received 
treatment for any disease. Patients with systolic pressure > 180 and/or diastolic 
pressure > 110 mmHg) were excluded. The study was conducted in accordance with the 
guidelines set by the Declaration of Helsinki, and the Institutional Review Boards of the 
University of Texas Southwestern Medical Center and Presbyterian Hospital of Dallas 
approved the study. All participants provided informed consent in writing.
5Instrumentation
Finger photoplethysmography (Finapres, Ohmeda, Madison, WI) was used to 
measure beat-to-beat changes in BP. Intermittent cuff BP was measured at the upper 
arm using electrosphygmomanometry (SunTech Medical, Inc., Morrisville, NC). CBF- 
velocity (CBFV) was recorded in the middle cerebral artery (MCA) using transcranial 
Doppler (TCD, Multiflow, DWL Germany). The Doppler probe was placed over the 
subject’s temporal window and fixed at a constant angle with a probe holder that was 
custom made to fit each subject’s facial bone structure. This technique allowed CBFV to 
be measured precisely at the same acoustic window and at the same angle for repeated 
studies.10 Heart rate was monitored using ECG. End-tidal CO2 (ETCO2) was monitored 
via a nasal cannula using a capnograph (Criticare Systems, Inc., Waukesha, WI ).
Protocol
Experiments were performed in the morning at least two hours after a light 
breakfast. The subjects refrained from heavy exercise and caffeinated or alcoholic 
beverages at least 24 hours before the tests. Baseline measurements of six min of 
beat-to-beat BP and CBFV during spontaneous breathing were recorded after at least 
30 min of supine rest.
We estimated CVMR using breath-by-breath changes in ETCO2, CBFV and BP.10 
Subjects were studied in the supine position to allow comparison with other imaging 
technology such as MRI or PET.18,19 To obtain a wide range of CO2 changes (from ~ 20 
to 60 mmHg ETCO2), a modified rebreathing protocol was used with a period of 
voluntary hyperventilation preceding rebreathing. Rebreathing was continued for 5 min, 
before returning to room air for recovery (4 min). A small amount of oxygen was bled 
into the rebreathing bag at the subject’s basal metabolic rate (estimated using the 
Harris-Benedict formula) to maintain arterial oxygen saturation (SaO2) constant.10
Antihypertensive treatment
After the baseline test, patients received low dose losartan/hydrochlorothiazide 
(50/12.5 mg once daily) for one week. If BP was not below a systolic pressure < 140 
mmHg and diastolic pressure < 90 mmHg the dose was increased to 100/25 mg. The
6short-term test (one to two weeks after start of treatment) was performed when this goal 
of BP control was reached. The long-term test was scheduled after three to four months 
of continued treatment. In patients, 24-h ambulatory BP (ABPM, Accutracker II,
SunTech, Inc.) was measured before treatment and repeated on the days before the 
short and long-term tests and at mid-term. In controls, 24-h ABPM was measured once 
at baseline and once before the long-term test. Patients took
losartan/hydrochlorothiazide in the morning 2-3 h before the study to ensure its optimal 
BP lowering effects. Throughout the study, BP was monitored at weekly intervals. In 
addition serum electrolytes and plasma renin activity and aldosterone were measured 
before and during treatment. Sample tubes were not chilled prior to or following blood 
collection. Serum separation tubes were used for aldosterone and EDTA for plasma 
renin activity. The samples were spun within 30-45 min after collection at 3560 RPM for 
20 min and frozen immediately at -  800C, until processing by National Reference 
Laboratory.
Data analysis
Off-line data analysis was performed using Acknowledge software (BIOPAC 
Systems, Inc, Goleta, CA). Baseline BP, HR and CBFV were obtained from the average 
of beat-to-beat data; ETCO2 was derived from the breath-to-breath data. 
Cerebrovascular conductance index (CVCI) was calculated as mean CBFV divided by 
mean BP for all beat-to-beat data.10 Since CBFV may be affected directly by changes in 
BP,20,21 estimations of CVMR based on CVCI may reveal intrinsic vascular responses to 
changes in CO2 . During hyperventilation and rebreathing, breath-to-breath values of 
mean CBFV, BP, CVCI, HR and ETCO2 were obtained. Towards the end of rebreathing, 
CBFV reached a plateau-phase; a similar plateau was observed for hypoventilation, 
indicating a steady-state. To compare with studies that measured steady-state 
conditions, the first part of data analysis was performed using these plateau values. 
Thus, maximum hypocapnic (~ 20 mmHg below baseline ETCO2) reduction in CBFV 
and CVCI (in %), maximum hypercapnic (~ 20 mmHg above baseline) increase in CBFV 
and CVCI (in %), and total range of change in CBFV and CVCI (hypocapnic + 
hypercapnic, in %) were derived. Next, CVMR was expressed as the ratio of % change
7in CBFV or CVCI over the whole range of changes in ETCO2 (hypocapnic + 
hypercapnic).
The second part of data-analysis focused on the dynamic responses of CBFV to the 
transient changes in ETCO2. CVMR was estimated nonlinearly for breath-to-breath 
changes in CBFV and CVCI.10 A 4 parameter logistic function was used for sigmoidal 
curve fitting, where model parameter a represents the total range of change in CBFV or 
CVCi; y0 is the maximum value of CBFV or CVCI during hypercapnia; x0 is the level of 
ETCO2 where vascular reactivity to changes in CO2 is maximal; and b is a constant that 
determines the sigmoidal shape of the curve (Fig. 1). Finally, linear regression of 
changes in CBFV and CVCI in the range of ETCO2 between 40-50 mmHg was 
performed. The slope of this regression is a robust method to estimate maximum
1 nvascular reactivity, 10 expected to be very sensitive to altered myogenic and structural
1 00 0^cerebrovascular properties, associated with hypertension.1,22,20 
Statistics
T-tests, and analysis of variance with Bonferroni correction for multiple 
comparisons, were used to compare the differences and interactions between the 
subject groups and the effects of antihypertensive treatment on baseline hemodynamics 
and CVMR (SigmaStat, version 3.11 Systat Software Inc.) All data were normally 
distributed (Q-Q plots). However, because PRA and aldosterone often are not normally 
distributed, analysis was repeated after log transformation, and with the non-parametric 
Friedman’s test. Data are presented as mean (SD), with their associated P values.
RESULTS 
Effects of Treatment
Significant reductions in BP were achieved within 1-2 weeks of treatment. This 
reduction was well maintained over the period of 3-4 months with the same dose of 
drugs (Table 1). The rapid dose adjustment within the first 1-2 weeks did not prompt 
subsequent dose reduction due to excess BP reduction or electrolyte disorders. All
8participants were "normal dippers” (10-20% nocturnal BP decline), and treatment 
affected nocturnal BP similarly as awake BP.
Before treatment, no differences in CBFV were observed between control subjects and 
patients with hypertension. CBFV did not change after short and long-term reductions in 
BP.
Plasma renin activity, but not aldosterone, was slightly higher at baseline in patients, 
and increased following treatment. LDL-cholesterol did not differ between patients and 
controls (117 (35) vs. 111 (32) mg/dL. Treatment did not importantly alter electrolytes, 
cholesterol or renal function (Table 1).
Estimation of CVMR
Maximum (plateau) changes in CBFV and CVCI with hyperventilation and 
rebreathing were similar in patients and controls, and neither short-term nor long-term 
treatment affected these values (Table 2). Examples of sigmoidal curve fitting of 
changes in CBFV and CVCI vs. ETCO2 are presented in Fig 1 and 2.. The results of 
non-linear parameter identification are summarized in Table 2. No differences in the 
model parameters were observed between patients and controls before or after 
treatment. The steep portion of changes in CBFV or CVCI to ETCO2 was identified in the 
range between 40-50 mmHg (Fig 1, 2). Estimation of CVMRmax in this range of ETCO2 
also did not differ between patients and controls nor was it influenced by treatment 
(Table 2). Group-averaged curves10 were similar for patients and controls, and are not 
shown.
Effects of CO2 on BP and HR
Patients and controls had similar changes in ETCO2 during hyperventilation and 
rebreathing (Fig 1, 2). In controls, hyperventilation decreased BP by 16 (SD 3) mmHg 
and increased HR by 17 (SD 11) bpm. Rebreathing increased BP by 27 (SD 14) mmHg 
without a change in HR. In patients, hyperventilation lowered BP by 21 (SD 12) mmHg 
and increased HR by 14 (SD 10) bpm. During rebreathing, BP increased by 25 (SD 8) 
mmHg, without a change in HR. Neither short-term nor long-term treatment altered the 
BP and HR response to CO2.
9DISCUSSION
This study assessed cerebral vasomotor reactivity to CO2 , using a recently
1 ndeveloped modified rebreathing method , in patients with untreated mild to moderate 
hypertension. There are four major findings. In contrast with existing reports, there was 
no difference in CVMR between patients and controls. With treatment, lowering of BP 
within 1-2 weeks with losartan/hydrochlorothiazide did not reduce CVMR, despite 
evidence for compensatory cerebral vasodilatation. Moreover, long-term BP control with 
this regimen, which results in inhibition of angiotensin II, had no effect on CVMR or 
cerebrovascular conductance. Finally, there was no difference in the BP and HR 
responses to CO2 stimuli between patients and controls, and these responses were not 
influenced by antihypertensive treatment.
Normal CVMR in hypertension
Troisi et al., using a breath hold index with TCD, found reduced CVMR in 
hypertensive subjects (aged 34 (SD 7) y), which was partially restored with atenolol.8 
The breath hold index describes vascular reactivity in a small hypercapnic range and 
provides no information on changes in ETCO2 or BP. Serrador et al. reported reduced 
CVMR (TCD) in controlled and uncontrolled hypertension without co-morbidity.9 Their 
data were corrected for a hypothetical effect of cerebral autoregulation. Without this 
correction the difference between patients and controls was lost.9 Hypertensive subjects 
with reduced CVMR (TCD) in the study by Maeda et al. all had advanced 
cerebrovascular disease.7 Finally, the reported reduction in CVMR (perfusion MRI) by 
Kario et al. 6 was limited to patients with both hypertension and diabetes.
Two studies found normal CVMR in hypertension. Tominaga et al. studied 9 
patients without cerebrovascular disease.24 The Xenon- method used to measure CBF 
allowed for only 3-5 measurements in the hypocapnic-hypercapnic range (20-55 mm 
Hg). Oku et al. studied 8 hypertensive patients with minimal or no cerebrovascular
A Q
disease.18 Only 2 measurements of CBF using PET were performed, before and after 
acetazolamide injection to induce hypercapnia). Our study adds by exploring a much
10
wider range of changes in CO2, by strongly increasing the number of CBF 
measurements, and by investigating transient changes in CO2, CBFV and CVCI together, 
to account for alterations in BP during CO2 stimuli.
Direct comparisons between studies is complicated because different populations 
were studied. We studied newly diagnosed, relatively healthy patients, whereas others 
included patients known to have hypertension as well as patients with co-morbidities, 
indicating that there may be important differences in the duration of hypertensive 
disease between studies. Nonetheless, CVMR was normal in these different groups, 
and impaired CVMR in these studies was limited to patients with co-existing diabetes 
and/or evidence for cerebrovascular disease.6,25,26 The presence of cerebrovascular 
disease may reflect a longer disease duration or it may point towards increased 
susceptibility for cerebrovascular disease in certain hypertensive patients. Consistent 
with this, CVMR remains normal in spontaneously hypertensive rats, whereas CVMR is 
impaired in the stroke-prone genetic variant, at advanced age when cerebrovascular
0~7disease has developed.27
Effects of treatment on CVMR
We did not observe a reduction in CVMR following BP reduction with treatment. 
Given that the study was powered to detect a small reduction in CVMR, this suggests 
one of the following: the amount of BP reduction was too small to affect CVMR, or 
losartan had beneficial effects on remodeling or cerebral autoregulation.
BP reduction and CVMR
CVMR is reduced in patients with carotid artery stenosis, who have reduced 
perfusion pressure and compensatory cerebral vasodilatation.4528 Reduction in CVMR
o q  o n  o  a
was also observed after acute reduction in BP in animals 29,30 and human subjects.31 
The reduction in BP in our study was smaller and more gradual than that in the acute 
hypotension experiments, where BP was rapidly reduced below the normal 
autoregulation range.29,31 The reduction in BP is also not likely to approximate the 
reduction in perfusion pressure caused by a severe carotid artery stenosis. Moreover, 
the magnitude of vasodilatation to compensate the BP reduction may be too small to
11
influence the much stronger CO2- induced vasodilatation. For example, for a 20% 
reduction in perfusion pressure, CBF can be maintained constant by an increase in 
cerebral blood vessel diameter o f« 6%. However, maximum hypercapnia, associated 
with a 100% increase in flow, brings about a 20% increase in diameter. Finally, 
vasodilatation in response to BP reduction may be mediated through different cerebral 
vessels than CO2-induced vasodilatation. The latter is largely determined by smaller 
(intraparenchymal) cerebral arteries, arterioles and capillaries,32 whereas the former is 
more determined by larger (extraparenchymal) vessels: under normal conditions, larger 
arteries (diameter >200 ^im) account fo r« 40 % of total cerebral vascular resistance, but
qo
their relative contribution increases in chronic hypertension.33 In hypertensive rats with 
BP « 160 mmHg (controls: 98 mmHg), pial arteriolar pressure was only « 80 mmHg 
(controls: 60 mmHg). 34 Thus, microvessels may retain normal vascular reactivity to CO2 
as they are protected by the resistance changes in larger arteries;33 alternatively, the 
adaptations that take place in larger arteries as a result of either hypertension or BP 
lowering are not reflected in CVMR.
Effects of angiotensine II blockade
We have studied the effects of losartan on CVMR after 1-2 weeks and again after 12 
weeks of treatment. Should losartan have a beneficial effect on cerebral remodeling and 
endothelial function, an improvement of CVMR with treatment would have been 
expected and CVMR would have increased between 2 and 12 weeks. One other study 
(the study by Oku et al. cited above) has investigated the effects of losartan on CVMR, 
and found no change in CVMR in 8 hypertensive patients after 8-23 weeks of treatment.
A Q
18 Only two measurements of CBF were performed and only in the hypercapnic range, 
using acetazolamide. A second study investigated the effect of 12-16 weeks of 
candesartan, and observed reduced CVMR using MRI in hypertensives with diabetes 
(n=20) with improvement following treatment.6 Patients with hypertension alone (n=20) 
had no reduction or change in CVMR. Cerebrovascular disease (multiple infarcts on 
MRI) was present in resp. 50 and 25 % of these patients. Losartan beneficially affected 
cerebral autoregulation in animal studies.15 There was however no difference in 
autoregulation in patients with hypertension before and after treatment with losartan.16
12
CBFV was maintained stable with reductions in BP following treatment, meaning that 
compensatory vasodilatation took place as shown by the increase in CVCI (Table 2). 
This however did not reduce CVMR. This study was not designed to disentangle 
interactions between cerebral autoregulation and vasomotor reactivity, which are two 
different systems. The stable cerebral perfusion and CVRM following BP lowering 
treatment with losartan/hydrochlorothiazide neither proofs nor refutes beneficial effects 
of losartan on the cerebral circulation, however, the absence of a difference in these 
parameters between short term and long term treatment does not indicate such 
beneficial effects.
BP response to CO2
Hypercapnia, through central chemoreceptors, causes sympathetic activation which in 
turn results in elevated BP due to the combined effects of an increase in cardiac output 
and peripheral vascular resistance.10,35,36 Hypertension is associated with increased 
baseline sympathetic activity,37,38 however whether this leads to an enhanced effect of 
hypercapnia on BP has not been addressed. We found no difference in BP and HR 
response between untreated patients with hypertension and controls, and 
antihypertensive treatment did not alter the BP and HR responses to CO2. Possibly, 
despite the difference in baseline activity, sympathetic responses are similar in
0 7
hypertension and controls. Alternatively, the magnitude of CO2 induced sympathetic 
activation obscures the much smaller difference in baseline activity.36,37,38
Limitations of this study
The limitations imposed by the measurement of CBF using TCD, as well as the 
limitations specific to the method used to estimate CVMR have been discussed. 10,39,40,41 
The flow-velocity in the MCA measured by TCD is determined by CBF and by the 
diameter of the MCA. Therefore, changes in CBFV reflect changes in CBF only if the 
MCA diameter is constant. During hypotension, hypocapnia and hypercapnia in healthy 
subjects and neurosurgical patients, MCA diameter was unchanged or showed less than 
4 % change.40,41 Studies in hypertensive patients are lacking. Measurements of isolated 
MCA from spontaneously hypertensive rats indicate a 10 % change in diameter with
13
large changes in mean BP from 40 to 140 mmHg,42 suggesting that in our study, small 
changes in MCA diameter cannot be excluded. Such changes would have led to a 
finding of reduced CBFV after treatment. The relatively narrower MCA lumen in 
hypertensive patients 42 might increase CBFV, overestimating CBF, and subsequent 
lumen increase following normalization of BP would then lower CBFV, underestimating 
CBF.
Nevertheless, our results are concordant with results obtained with other modalities 
(such as MRI and PET) to measure CBF during hypo- and hypercapnia,6,18,24 which 
suggests that possible confounding effects of changes in MCA diameter in our study 
had minimal effect on outcome or interpretation.
As with most other studies that have investigated CVMR in hypertension, this is a study 
in a small number of subjects. Our method has good reproducibility, in line with other 
methods to estimate CVMR.10 A clinically significant reduction in CVMR can be identified
oo
even with this small number of subjects.28 Indeed, this study was adequately powered to 
detect small differences in CVMR.
In summary, we have studied untreated patients with mild to moderate 
hypertension in the absence of diabetes or cerebrovascular disease, and have shown 
that CVMR was not affected. Previous reports of impaired CVMR with hypertension may 
be explained by co-morbid severe cerebrovascular disease and/or diabetes. We have 
also shown that despite significant hemodynamic alterations induced by the initiation of 
antihypertensive treatment, CVMR remained unaffected. We have recently observed 
that cerebral autoregulation was not altered after short-term and long-term 
antihypertensive treatment, indicating that cerebral vasodilatory responses to reductions 
in perfusion pressure were maintained.16 Together these observations suggest that the 
cerebrovascular adaptations to a reduction in perfusion pressure are not associated with 
exhaustion of cerebrovascular reserve. Further studies may elucidate whether the 
finding of impaired CVMR in a patient with hypertension may herald an increased risk for 
cerebrovascular disease.
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Figure legends
Figure 1. Example of the analysis of vasomotor reactivity in a healthy subject.
Results of the modified rebreathing test and sigmoidal curve-fitting, displaying the 
changes in cerebral blood flow velocity (CBFV, left) and cerebrovascular conductance 
index (CVCI, right) in response to end-tidal CO2 (ETCO2) in a healthy control subject. 
The black dots represent data averaged over the period of one breath, during 
hyperventilation (data points below 100 %) and CO2-rebreathing (data points above 
100%). The sigmoid line is the result of 4-parameter exponential curve fitting of these
1 ndata points (see text and for more details). The left graph offers a graphic 
representation of these 4 identified parameters. "a” is the total range of changes in CVCi 
or CBFV, "Y0” is the maximum value, "X0” is the level of ETCO2 that exhibits highest 
CO2 sensitivity, and "b” is a factor that determines the shape of the regression curve.
Figure 2. Example of vasomotor reactivity analysis in a hypertensive patient.
Results of the modified rebreathing test and sigmoidal curve-fitting in a hypertensive 
patient. Representation of black dots and sigmoid curve as in figure 1. Top: Changes in 
cerebral blood flow velocity (CBFV) in response to end-tidal CO2 (ETCO2) at baseline 
(A), and after 1 -2 weeks (B) and 3 months (C) of treatment with 
losartan/hydrochlorothiazide. Bottom: Changes in cerebrovascular conductance index 
(CVCI) in response to ETCO2 at baseline (D), and after 1-2 weeks (E) and 3 months (F) 
of treatment.
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Table 1. Characteristics of hypertensive patients and controls at baseline and follow-up
Baseline 1 -2 weeks 3-4 months
Variables Control Hypertension Control Hypertension Control Hypertension
Age, y 46 (10) 52 (9)
Height, cm 180 (9) 178 (10)
Weight, kg 87 (16) 88 (19)
BMI, kg/m2 27 (3) 27 (4)
Creatinine , mg/dL 1.02 (0.10) 1.01 (0.19) 0.97 (0.16) 0.96 (0.13)
Potasssium,mEq/L 4.2 (0.21) 4.5 (0.51) 4.5 (0.81) 4.1 (0.27)f
PRA, ng/L 0.67 (0.44) 0.99 (1.04) 3.06 (3.09) 0.78 (0.71) 2.37 (2.40)
Aldosterone, ng/dL 4.45 (2.30) 6.27 (3.40) 6.14 (2.76) 4.23 (1.70) 6.07 (4.42)
24 h ABPM
awake
SBP, mmHg 122 (7) 148 (12)* -- 130 (15)f 124 (7) 1 2 5 (10)f
DBP, mmHg 75 (7) 89 (7)* -- 80 (9 )f 76 (7) 77 (7 )f
HR, bpm 69 (8) 77 (8)* -- 78 (7) 72 (8) 77 (10)
nighttime
SBP, mmHg 110 (10) 129 (17)* -- 113 (9 )f 117 (12) 109 (12)f
DBP, mmHg 68 (10) 77 (7) -- 70 (6) 70 (9 )f 69 (7 )f
HR, bpm 64 (8) 68 (10) -- 70 (9) 67 (9) 66 (10)
CBFV, cm/s 49 (11) 49 (12) -- 51 (14) 51 (13) 51 (14)
CVCI, cm/s/mmHg 0.51 (0.11) 0.45 (0.11) -- 0.53 (0.13)f 0.52 (0.10) 0.55 (0.15)f
20
ETCO2 , mmHg 38 (5) 36 (4) -- 36 (5) 38 (3) 38 (5)
Data are mean (SD), n = 8 for control, n = 11 for hypertension. BMI, body mass index. PRA, plasma renin activity. SBP, 
systolic blood pressure, DBP, diastolic blood pressure, HR, heart rate. These measurements were obtained from 24 h 
ambulatory BP measurements (ABPM, presented as awake and nighttime averages). Nighttime BP was significantly lower 
than awake BP in patients and controls ( p < 0.01). Mid-term BP (at 6 weeks) was measured in patients only and was 127 
(8)/ 80 (4) mmHg. CBFV, cerebral blood flow velocity, CVCI, cerebrovascular conductance, ETCO2, end-tidal CO2. These 
measurements were obtained under supine resting conditions. * P < 0.05 for comparison between control subjects and 
patients with hypertension. f  P < 0.01 for comparisons between baseline and treatment for patients with hypertension.
2l
Table 2. Estimates of CVMR in controls and patients with hypertension before and during treatment
Vasomotor reactivity Control
Baseline 3-4 months Baseline
Hypertension
1 -2 weeks 3-4 months
Hypocapnia
minimum flow CBFV, % 60 (9) 65 (9) 66 (12) 66 (13) 66 (11)
minimum conductance CVCI, % 65 (10) 67 (10) 73 (9) 77 (7) 75 (12)
Hypercapnia
maximum flow CBFV, % 216 (26) 218 (29) 220 (35) 220 (33) 214 (42)
maximum conductance CVCI, % 172 (26) 176 (16) 180 (28) 180 (25) 172 (31)
Logistic model parameters
a-CBFV, % 178 (26) 160 (31) 197 (73) 187 (53) 169 (57)
a-CVCI, % 114 (22) 106 (15) 121 (73) 104 (33) 107 (44)
Y0-CBFV, % 227 (24) 213 (35) 241 (56) 242 (55) 221 (57)
Y0-CVCI, % 180 (25) 177 (19) 200 (64) 183 (31) 182 (47)
X0-CBFV, mmHg 48 (3) 45 (6) 49 (6) 49 (7) 51 (8)
X0-CVCI, mmHg 47 (3) 46 (2) 47 (4) 45 (4) 47 (3)
b-CBFV, constant 0.17 (0.0) 0.22 (0.0) 0.17 (0.1) 0.18 (0.1) 0.18 (0.1)
b-CVCI, constant 0.25 (0.1) 0.30 (0.1) 0.28 (0.1) 0.33 (0.1) 0.31 (0.1)
Estimations of CVMR
Logistic regression CVMRmax- 7.5 (0.8) 8.6 (1.7) 8.8 (1.7) 9.1 (4.1) 8.9 (2.5)
22
CBFV, %/mmHg 
CVMRmax- 
CVCI, %/mmHg 
Linear regression 40-50 Mm CVMRmax- 
Hg CBFV, %/mmHg
CVMRmax- 
CVCI, %/mmHg 
Ratio CVMR-CBFV, %/mmHg
CVMR-CVCI, %/mmHg
7.0 (1.5) 8.0 (1.8)
7.8 (0.9) 7.9 (1.6) 
5.9(1.6) 6.0 (1.9)
3.8 (0.6) 4.0 (0.6)
2.8 (0.5) 2.9 (0.4)
7.3 (1.7) 7.9 (2.5) 7.4 (1.4)
7.9 (1.5) 7.6 (1.5) 8.3 (1.4)
6.0 (1.1) 6.6 (1.3) 6.3 (1.4)
4.2 (1.0) 3.9 (1.2) 4.0 (1.2)
4.2 (1.0) 4.0 (1.3) 3.9 (1.4)
Data are mean (SD). N=7 for control, n=11 for hypertension. CBFV, cerebral blood flow velocity, CVCI, cerebrovascular 
conductance index. Minimum and maximum values during hypocapnia and hypercapnia represent observed values for 
CBFV and CVCI. Logistic model parameters represent values for CBFV and CVCI predicted from logistic regression. a- 
CBFV, total change in CBFV from maximum hypocapnia to maximum hypercapnia in % of baseline. Note that a-CBFV 
compares to the difference between maximum flow and minimum flow. a-CVCI, similar for CVCI. Y0-CBFV, maximum 
value for CBFV during hypercapnia, relative to baseline. Note that YO-CBFV compares to maximum flow. Y0-CVCI, 
similar for CVCI. X0, value for end-tidal CO2 where CVMRmax, from logistic regression, occurs. CVMRmax, maximum 
vasomotor reactivity identified with either logistic regression or linear regression in the ETCO2 range between 40-50 mm 
Hg (see text). CVMR, index of vasomotor reactivity representing the ratio of change in CBFV or CVCI over ETCO2 in the 
total hypocapnic and hypercapnic range. There were no significant differences between controls and patients or between 
baseline and follow-up (P > 0.1).
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